<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041324</url>
  </required_header>
  <id_info>
    <org_study_id>SB-913-1602</org_study_id>
    <nct_id>NCT03041324</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and
      plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913. SB-913 is an
      intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts
      a correct copy of the IDS gene into the Albumin locus in hepatocytes with the goal of
      lifelong therapeutic production of the IDS enzyme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to provide long term expression of IDS and improve the
      current clinical outcome of enzyme replacement therapy (ERT) in subjects with MPS II, a
      recessive lysosomal storage disorder that results from mutations in the gene encoding IDS.
      SB-913 is a therapeutic for ZFN-mediated genome editing which will be delivered by
      adeno-associated virus (AAV)-derived vectors. SB-913 is intended to function by placement of
      the corrective copy of IDS transgene into the genome of the subject's own hepatocytes, under
      the control of the highly expressed endogenous albumin locus, and is expected to provide
      permanent, liver-specific expression of Iduronate 2-Sulfatase for the lifetime of an MPS II
      patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in subjects who receive SB-913 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-913 on IDS activity</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Change from baseline in clinical laboratory measurement of IDS activity measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-913 on urine glycosaminoglycans (GAG) levels</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>Change from baseline in total GAG, DS GAG, and HS GAG (/creatinine ratio) measured in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAV2/6 clearance in plasma, saliva, urine, stool, and semen</measure>
    <time_frame>Up to 36 months after the SB-913 infusion</time_frame>
    <description>AAV2/6 clearance by measuring vector genomes in plasma, saliva, urine, stool, and semen by PCR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>MPS II</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SB-913 at low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SB-913 at medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SB-913 at high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-913</intervention_name>
    <description>Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male &gt;18 years of age

          -  Clinical diagnosis of attenuated MPS II (based on evidence of hepatosplenomegaly,
             dysostosis multiplex by X-ray, valvular heart disease, or obstructive airway disease)

        Exclusion Criteria:

          -  Known to be unresponsive to ERT

          -  Neutralizing antibodies to AAV 2/6

          -  Serious intercurrent illness or clinically significant organic disease (unless
             secondary to MPS II)

          -  Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or
             hepatitis C or HIV 1/2

          -  Lack of tolerance to idursulfase treatment with significant IARs or occurrence of
             anaphylaxis

          -  Markers of hepatic dysfunction

          -  Creatinine ≥ 1.5 mg/dL

          -  Contraindication to the use of corticosteroids for immunosuppression

          -  Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use
             (topical treatment allowed)

          -  Participation in prior investigational drug or medical device study within the
             previous 3 months

          -  Prior treatment with a gene therapy product

          -  Elevated or abnormal circulating α-fetoprotein (AFP)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>send email</phone>
    <email>clinicaltrials@sangamo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Nicholas</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>5241</phone_ext>
      <email>JiNicholas@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Paul Harmatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Katz</last_name>
      <phone>312-227-6764</phone>
      <email>rkatz@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Dodsworth</last_name>
      <phone>312-227-6128</phone>
      <email>cDodsworth@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Burton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Grover</last_name>
      <phone>612-672-5151</phone>
      <email>pgrover1@fairview.org</email>
    </contact>
    <investigator>
      <last_name>Chester Whitley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine, Neurogenetics Division</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Ferraris</last_name>
      <phone>212-263-0139</phone>
      <email>Marissa.ferraris@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Heather A. Lau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Preiss, RN</last_name>
      <phone>919-842-5731</phone>
      <email>heather_preiss@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Joesph Muenzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Bailey</last_name>
      <phone>513-636-4507</phone>
      <email>laurie.bailey@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Carlos E Prada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Nesom</last_name>
      <phone>267-426-1368</phone>
      <email>nesomg@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Can Ficicioglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS ll</keyword>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>Hunter syndrome</keyword>
  <keyword>gene editing</keyword>
  <keyword>gene therapy</keyword>
  <keyword>zinc finger</keyword>
  <keyword>ZFN</keyword>
  <keyword>SB-913</keyword>
  <keyword>rare</keyword>
  <keyword>genetic</keyword>
  <keyword>DNA</keyword>
  <keyword>Sangamo</keyword>
  <keyword>Genomic editing</keyword>
  <keyword>Champions</keyword>
  <keyword>Hunter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

